PDF(Pubmed)
Abstract：
UNASSIGNED: To study vitreoretinal interface (VRI) abnormalities in diabetic macular edema (DME) and the influence of these on the effectiveness of intravitreal anti-vascular endothelial growth factor (VEGF) therapy.
UNASSIGNED: VRI status and central retinal thickness (CRT) were evaluated using line and 3D-reference scans obtained using spectral domain-optical coherence tomography RTVue-100 before and 1 month after intravitreal anti-VEGF injection (IVI). VRI status was categorized into five subgroups: normal VRI, retinal surface wrinkling associated with the eccentric epiretinal membrane (ERM), ERM involving the macular center, vitreomacular adhesion (VMA), and vitreomacular traction (VMT).
UNASSIGNED: A total of 105 eyes of 89 patients were included in the study. One month after IVI, the mean change of CRT in normal VRI eyes and eyes with VRI abnormalities was -128.0±144.7 µm and -53.0±96.4 µm (p<0.05), respectively. The mean change of CRT 1 month after IVI in each subgroup with VRI abnormalities, apart from the subgroup with retinal wrinkling associated with eccentric ERM, was statistically significantly lower compared to the eyes with normal VRI (p<0.05).
UNASSIGNED: VRI abnormalities significantly reduce the effectiveness of intravitreal anti-VEGF therapy in eyes with DME. Eyes with noticeable changes of VRI, including ERM involving the macular center, VMA, and VMT have a poorer response to anti-VEGF therapy compared to eyes with normal VRI or eccentric ERM.
UNASSIGNED: VRI status and central retinal thickness (CRT) were evaluated using line and 3D-reference scans obtained using spectral domain-optical coherence tomography RTVue-100 before and 1 month after intravitreal anti-VEGF injection (IVI). VRI status was categorized into five subgroups: normal VRI, retinal surface wrinkling associated with the eccentric epiretinal membrane (ERM), ERM involving the macular center, vitreomacular adhesion (VMA), and vitreomacular traction (VMT).
UNASSIGNED: A total of 105 eyes of 89 patients were included in the study. One month after IVI, the mean change of CRT in normal VRI eyes and eyes with VRI abnormalities was -128.0±144.7 µm and -53.0±96.4 µm (p<0.05), respectively. The mean change of CRT 1 month after IVI in each subgroup with VRI abnormalities, apart from the subgroup with retinal wrinkling associated with eccentric ERM, was statistically significantly lower compared to the eyes with normal VRI (p<0.05).
UNASSIGNED: VRI abnormalities significantly reduce the effectiveness of intravitreal anti-VEGF therapy in eyes with DME. Eyes with noticeable changes of VRI, including ERM involving the macular center, VMA, and VMT have a poorer response to anti-VEGF therapy compared to eyes with normal VRI or eccentric ERM.
摘要：
■研究糖尿病性黄斑水肿（DME）的玻璃体视网膜界面（VRI）异常及其对玻璃体内抗血管内皮生长因子（VEGF）治疗有效性的影响。
■在玻璃体内注射抗VEGF（IVI）之前和之后1个月，使用谱域光学相干断层扫描RTVue-100获得的线和3D参考扫描评估VRI状态和中央视网膜厚度（CRT）。VRI状态分为五个亚组：正常VRI，与偏心视网膜前膜（ERM）相关的视网膜表面起皱，涉及黄斑中心的ERM，玻璃体黄斑粘连(VMA),和玻璃体黄斑牵引（VMT）。
■本研究共纳入89例患者的105只眼。IVI后一个月，正常VRI眼和VRI异常眼的CRT平均变化为-128.0±144.7µm和-53.0±96.4µm(p<0.05),分别。VRI异常各亚组IVI后1个月CRT的平均变化,除了与偏心ERM相关的视网膜皱纹亚组，与具有正常VRI的眼睛相比,统计学上显著降低(p<0.05)。
■VRI异常显着降低了DME患者玻璃体内抗VEGF治疗的有效性。眼睛有明显的VRI变化，包括涉及黄斑中心的ERM，VMA,与正常VRI或偏心ERM的眼睛相比，VMT对抗VEGF治疗的反应较差。
■在玻璃体内注射抗VEGF（IVI）之前和之后1个月，使用谱域光学相干断层扫描RTVue-100获得的线和3D参考扫描评估VRI状态和中央视网膜厚度（CRT）。VRI状态分为五个亚组：正常VRI，与偏心视网膜前膜（ERM）相关的视网膜表面起皱，涉及黄斑中心的ERM，玻璃体黄斑粘连(VMA),和玻璃体黄斑牵引（VMT）。
■本研究共纳入89例患者的105只眼。IVI后一个月，正常VRI眼和VRI异常眼的CRT平均变化为-128.0±144.7µm和-53.0±96.4µm(p<0.05),分别。VRI异常各亚组IVI后1个月CRT的平均变化,除了与偏心ERM相关的视网膜皱纹亚组，与具有正常VRI的眼睛相比,统计学上显著降低(p<0.05)。
■VRI异常显着降低了DME患者玻璃体内抗VEGF治疗的有效性。眼睛有明显的VRI变化，包括涉及黄斑中心的ERM，VMA,与正常VRI或偏心ERM的眼睛相比，VMT对抗VEGF治疗的反应较差。
